Pdb78 Willingness-to-Pay for Diabetes Drug Therapy Based on Meta-Analysis Results

Willingness to pay for physician services in Ukraine and other central and eastern European countries : application of stated preferences techniques to the assessment of patient charges

“…Hancock-Howard et al, 2012). The majority of the DCE studies, however, apply integration of marginal WTP across the changes in the attributes, which are deemed to represent the benefit (Whitty et al, 2013;Mattsson et al, 2013;Carroll et al, 2013;Regier et al, 2012;Marti, 2012;Kjaer et al, 2012;Jendle et al, 2012;Hancock-Howard et al, 2012;Glenngard et al, 2012). This approach is however not always possible to apply as it requires comparison of a valued benefit with certain attributes to a meaningful alternative with its own level of attributes.…”

“…Mattsson et al, 2013;Regier et al, 2012) or use evidence on the characteristics of available alternatives (e.g. Jendle et al, 2012). Others use the total variation change in all the attributes (e.g.…”

“…Kjaer et al, 2012), glucose related problems (e.g. Jendle et al, 2012), smoking cessation (e.g. Marti, 2012).…”

“…Mattsson et al, 2013;Moia et al, 2013;Naik-Panvelkar et al, 2012;Whitty et al, 2013), specific diagnostic, treatment procedure or a drug (e.g. Lynn et al, 2013;Hansen et al, 2013;Regier et al, 2012;Marti, 2012;Jendle et al, 2012;Hodgkins et al, 2012;Havet et al, 2012;Hancock-Howard et al, 2012;Glenngard et al, 2012), screening program (e.g. Carroll et al, 2013;Dixon et al, 2012;Sogaard et al, 2012), vaccination (e.g.…”

“…Naik-Panvelkar et al, 2012), specific efficacy of the treatment (e.g. Marti, 2012;Jendle et al, 2012;Hodgkins et al, 2012;Glenngard et al, 2012). Other studies specify potential changes in the factors that may have health impacts like detection rates for screening and diagnostics (e.g.…”